Search

Your search keyword '"Sayegh, Hoda"' showing total 23 results
Start Over Author "Sayegh, Hoda"
23 results on '"Sayegh, Hoda"'

7. Hand Edema in Patients at Risk of Breast Cancer--Related Lymphedema: Health Professionals Should Take Notice

Author

Brunelle, Cheryl L., Swaroop, Meyha N., Skolny, Melissa N., Asdourian, Maria S., Sayegh, Hoda E., and Taghian, Alphonse C.

Subjects
Physical therapy -- Health aspects -- Research, Lymphedema -- Research -- Risk factors -- Care and treatment, Medical personnel -- Practice, Cancer patients -- Care and treatment -- Health aspects, Breast cancer -- Complications and side effects -- Research -- Care and treatment, Edema -- Research -- Risk factors -- Care and treatment, Health
Abstract

Background. There is little research on hand edema in the population at risk for breast cancer-related lymphedema (BCRL). Objectives. Study aims included reporting potential importance of hand edema (HE) as a risk factor for progression of edema in patients treated for breast cancer at risk for BCRL, reporting risk factors for BCRL, and reporting treatment of HE. Design/Methods. This was a retrospective analysis of 9 patients treated for breast cancer in Massachusetts General Hospital's lymphedema screening program who presented with isolated HE. Limb volumes via perometry, BCRL risk factors, and HE treatment are reported. Results. Edema was mostly isolated to the hand. Three patients had arm edema >5% on perometry; and 2 of these had edema outside the hand on clinical examination. Patients were at high risk of BCRL with an average of 2.9/5 known risk factors. Arm edema progressed to >10% in 2 high-risk patients. Treatment resulted in an average hand volume reduction of 10.2% via perometry and improvement upon clinical examination. Limitations. The small sample size and lack of validated measures of subjective data were limitations. Conclusions. In this cohort, patients with HE carried significant risk factors for BCRL. Two out of 9 (22%), both carrying 24/5 risk factors, progressed to edema >10%. Isolated HE may be a prognostic factor for edema progression in patients treated for breast cancer at risk for BCRL. Further research is warranted., As the long-term survival rate for breast cancer improves, there is an increasing focus on the sequelae of breast cancer treatment that may affect function and/or quality of life. There [...]

Published
2018
Full Text
View/download PDF

12. Timing of Lymphedema Following Treatment for Breast Cancer: When Are Patients Most At-Risk?

Author

McDuff, Susan G. R., Mina, Amir I., Brunelle, Cheryl L., Salama, Laura, Warren, Laura E. G., Abouegylah, Mohamed, Swaroop, Meyha, Skolny, Melissa N., Asdourian, Maria, Gillespie, Tessa, Daniell, Kayla, Sayegh, Hoda E., Naoum, George, Zheng, Hui, and Taghian, Alphonse G.

Subjects
Adult, Aged, 80 and over, Risk, Lymphatic Irradiation, Time Factors, Sentinel Lymph Node Biopsy, Incidence, Breast Neoplasms, Middle Aged, humanities, Article, body regions, Young Adult, hemic and lymphatic diseases, Humans, Lymph Node Excision, Female, Lymphedema, Prospective Studies, Aged, Proportional Hazards Models
Abstract

The purpose of the study was to determine when the risk of lymphedema is highest after treatment of breast cancer and which factors influence the time course of lymphedema development.Between 2005 and 2017, 2171 women (with 2266 at-risk arms) who received surgery for unilateral or bilateral breast cancer at our institution were enrolled. Perometry was used to objectively assess limb volume preoperatively, and lymphedema was defined as a ≥10% relative arm-volume increase arising3 months postoperatively. Multivariable regression was used to uncover risk factors associated with lymphedema, the Cox proportional hazards model was used to calculate lymphedema incidence, and the semiannual hazard rate of lymphedema was calculated.With a median follow-up of 4 years, the overall estimated 5-year cumulative incidence of lymphedema was 13.7%. Significant factors associated with lymphedema on multivariable analysis were high preoperative body mass index, axillary lymph node dissection (ALND), and regional lymph node radiation (RLNR). Patients receiving ALND with RLNR experienced the highest 5-year rate of lymphedema (31.2%), followed by those receiving ALND without RLNR (24.6%) and sentinel lymph node biopsy with RLNR (12.2%). Overall, the risk of lymphedema peaked between 12 and 30 months postoperatively; however, the time course varied as a function of therapy received. Early-onset lymphedema (12 months postoperatively) was associated with ALND (HR [hazard ratio], 4.75; P .0001) but not with RLNR (HR, 1.21; P = .55). In contrast, late-onset lymphedema (12 months postoperatively) was associated with RLNR (HR, 3.86; P = .0001) and, to a lesser extent, ALND (HR, 1.86; P = .029). The lymphedema risk peaked between 6 and 12 months in the ALND-without-RLNR group, between 18 and 24 months in the ALND-with-RLNR group, and between 36 and 48 months in the group receiving sentinel lymph node biopsy with RLNR.The time course for lymphedema development depends on the breast cancer treatment received. ALND is associated with early-onset lymphedema, and RLNR is associated with late-onset lymphedema. These results can influence clinical practice to guide lymphedema surveillance strategies and patient education.

Published
2018

13. Chronic Inflammation Permanently Reshapes Tissue-Resident Immunity in Celiac Disease

Author

Mayassi, Toufic, primary, Ladell, Kristin, additional, Gudjonson, Herman, additional, McLaren, James E., additional, Shaw, Dustin G., additional, Tran, Mai T., additional, Rokicka, Jagoda J., additional, Lawrence, Ian, additional, Grenier, Jean-Christophe, additional, van Unen, Vincent, additional, Ciszewski, Cezary, additional, Dimaano, Matthew, additional, Sayegh, Hoda E., additional, Kumar, Vinod, additional, Wijmenga, Cisca, additional, Green, Peter H.R., additional, Gokhale, Ranjana, additional, Jericho, Hilary, additional, Semrad, Carol E., additional, Guandalini, Stefano, additional, Dinner, Aaron R., additional, Kupfer, Sonia S., additional, Reid, Hugh H., additional, Barreiro, Luis B., additional, Rossjohn, Jamie, additional, Price, David A., additional, and Jabri, Bana, additional

Published
2019
Full Text
View/download PDF

14. Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy

Author

Abouegylah, Mohamed, primary, Braunstein, Lior Z., additional, Alm El-Din, Mohamed A., additional, Niemierko, Andrzej, additional, Salama, Laura, additional, Elebrashi, Mostafa, additional, Edgington, Samantha K., additional, Remillard, Kyla, additional, Napolitano, Brian, additional, Naoum, George E., additional, Sayegh, Hoda E., additional, Gillespie, Tessa, additional, Farouk, Mohamed, additional, Ismail, Abdelsalam A., additional, and Taghian, Alphonse G., additional

Published
2018
Full Text
View/download PDF

20. Classes of Anti-Neoplastic Agents Associated with Increased Risk of Cancer Therapy-Associated Hypertension and Management Strategies

Author

Sayegh, Hoda, Zagouras, Alexia, Neal, Joel W., Witteles, Ronald M., Zhu, Han, and Waliany, Sarah

Abstract

Hypertension (HTN) has been found to be the most common comorbidity in patients with cancer. In addition to increased prevalence of baseline HTN, patients with cancer may be at increased risk of HTN as a short- or long-term adverse event from cancer therapy. Different classes of cancer therapies have been implicated in the development of HTN, including inhibitors of vascular endothelial growth factor (VEGF), Bruton tyrosine kinase inhibitors, proteasome inhibitors, androgen deprivation therapy, and others. While some of these drugs may lead to increases in blood pressure through on-target effects (e.g. with VEGF inhibition), others may be associated with HTN from off-target mechanisms that are not always well-understood. The appropriate management of cancer therapy-associated HTN is also limited by a dearth of studies investigating HTN management specifically in cancer patients, leading to extrapolation of data from the general population. This manuscript aims to review the knowledge on incidence, mechanisms, and sequelae of cancer-therapy related HTN with different classes of anti-neoplastic agents. We further review management strategies as per consensus-based guidelines.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results